Value
8.0/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 6.0 |
| Fwd P/E | 9.1 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 11.2x
- ▸PEG: 0.01
- ▸Attractively valued
FENC · Why this verdict
Why Fennec Pharmaceuticals (FENC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Fennec's elite Rule of 40 score, positive free cash flow, and bullish technical breakout are counterbalanced by concentration in a single product and manufacturer plus recent insider selling, leaving the stock a hold rather than a clear add.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Fennec scores an elite Rule of 40 of 87 and is free-cash-flow positive (FCF margin 2%) despite reporting a GAAP net loss. Quality breakdown | The Rule of 40 score should stay elite and FCF should stay positive over the next 12 months as PEDMARK sales continue scaling. | →Stable |
| CounterA Rule of 40 score driven mostly by high revenue growth off a small base can decay quickly as the growth rate normalizes. | ||
Fennec's business is concentrated in a single product, PEDMARK, and depends on a single third-party contract manufacturer, creating two compounding concentration risks. Bear case | Revenue diversification beyond PEDMARK or added manufacturing redundancy should develop over the next 12 months to reduce single-point-of-failure risk. | ↓Deteriorating |
| CounterA focused commercial-stage biotech built around one approved product is a normal and often deliberate strategy, and manufacturing risk can be mitigated with backup supply agreements not visible in this data. | ||
The stock is in a technical breakout — a golden cross with price above all major moving averages and bullish MACD, with RSI at 58 (not yet overbought). Chart pattern detection | The breakout should hold, with price staying above key moving averages over the next several months. | →Stable |
| CounterBreakout setups on thinly-traded small caps frequently fail and reverse, especially without confirming volume or fundamental catalysts. | ||
Insiders sold a net of roughly 107,000 shares over 90 days (a bearish signal) while the risk profile carries 3 high and 1 medium concentration flags. Insider | Insider activity should shift toward neutral-to-bullish and concentration risk flags should decline over the next 12 months. | →Stable |
| CounterRoutine sales for tax or diversification purposes under pre-scheduled selling plans (Rule 10b5-1) are common and don't necessarily signal a negative insider view. | ||
The stock trades 24.1% below the analyst price target, offering a meaningful gap if the growth and cash-flow profile is sustained. Estimated upside | The stock should close a meaningful portion of the 24.1% gap toward the analyst target over the next 12 months. | →Stable |
| CounterLight analyst coverage noted elsewhere in the data can make the target itself unreliable, reducing confidence in the implied upside. | ||
Fennec scores an elite Rule of 40 of 87 and is free-cash-flow positive (FCF margin 2%) despite reporting a GAAP net loss.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should stay elite and FCF should stay positive over the next 12 months as PEDMARK sales continue scaling.
CounterA Rule of 40 score driven mostly by high revenue growth off a small base can decay quickly as the growth rate normalizes.
Fennec's business is concentrated in a single product, PEDMARK, and depends on a single third-party contract manufacturer, creating two compounding concentration risks.
↓DeterioratingBear case
- Expectation
- Revenue diversification beyond PEDMARK or added manufacturing redundancy should develop over the next 12 months to reduce single-point-of-failure risk.
CounterA focused commercial-stage biotech built around one approved product is a normal and often deliberate strategy, and manufacturing risk can be mitigated with backup supply agreements not visible in this data.
The stock is in a technical breakout — a golden cross with price above all major moving averages and bullish MACD, with RSI at 58 (not yet overbought).
→StableChart pattern detection
- Expectation
- The breakout should hold, with price staying above key moving averages over the next several months.
CounterBreakout setups on thinly-traded small caps frequently fail and reverse, especially without confirming volume or fundamental catalysts.
Insiders sold a net of roughly 107,000 shares over 90 days (a bearish signal) while the risk profile carries 3 high and 1 medium concentration flags.
→StableInsider
- Expectation
- Insider activity should shift toward neutral-to-bullish and concentration risk flags should decline over the next 12 months.
CounterRoutine sales for tax or diversification purposes under pre-scheduled selling plans (Rule 10b5-1) are common and don't necessarily signal a negative insider view.
The stock trades 24.1% below the analyst price target, offering a meaningful gap if the growth and cash-flow profile is sustained.
→StableEstimated upside
- Expectation
- The stock should close a meaningful portion of the 24.1% gap toward the analyst target over the next 12 months.
CounterLight analyst coverage noted elsewhere in the data can make the target itself unreliable, reducing confidence in the implied upside.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 3.9 |
| Net margin | 0.0 |
| Current ratio | 7.2 |
| FCF quality | 3.4 |
| Moat | 6.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 2%, FCF yield 0.3%)
- ▸Rule of 40: 87 (elite)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 85% YoY
Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.2 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 0.9 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 71%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 9.9 |
| notable moves | 7.0 |
- ▸Notable insider selling — $1,406,518 (0.378% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.7 |
| quality rank | 5.5 |
| growth rank | 8.0 |
- ▸Industry growth leader
Technical
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.9 |
| support resistance | 8.6 |
| 52w position | 5.6 |
Risk (lower is worse)
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 9.1 |
| days to cover | 8.8 |
| volatility | 0.5 |
| beta | 6.1 |
- ▸Concentration risks: 3 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Market cap $372M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (6)
- ASYMMETRY:5.1>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.9<4.5
- INSIDER:0.38%=HEAVY
Warning (0)
none
Reward-to-Risk
5.06
Upside
+48.5%
Downside
9.6%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 2.9<4.5 outcome against Growth at 10.0 and asymmetric R:R of 5.06.
The strongest dimensions are Growth at 10.0, Value at 8.0, and Sentiment at 7.6; the weakest are Momentum at 2.9, Catalyst at 3.3, and Quality at 4.7. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 5.06 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Product Concentration Risk
Trip ifPEDMARK-related revenue concentration falls below 70% of total revenue, or a second supply source is established.
- P2Elite Rule Of 40 With Gaap Loss
Trip ifRule of 40 score falls below 40 for 2 consecutive quarters.
- P3Bullish Breakout Technical Setup
Trip ifPrice closes below the 200-day moving average for more than 5 consecutive trading days.
- P4Insider Selling And Concentration Flags
Trip ifNet insider selling exceeds 200,000 shares over a rolling 90-day period.
- P5Gap To Analyst Target
Trip ifThe gap to the analyst target compresses below 10%, from the current 24.1%.